Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 127

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 127
---
 our products, which may vary significantly; |

| ● | expenditures that we may incur to acquire, develop or commercialize additional products and technologies; |

| ● | coverage and reimbursement policies with respect to our products, if approved or certified, and potential 
 future products that compete with our products;                                                           |

| ● | the cost of manufacturing our products, which may vary depending on the quantity of production and the 
 terms of our agreements with third-party suppliers and manufacturers; and                              |

| ● | future accounting pronouncements or changes in our accounting policies. |

| 51 |

The cumulative
effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result,
comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an
indication of our future performance. In addition, this variability and unpredictability could also result in our failing to meet the
expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations
of analysts or investors or below any forecasts we may provide to the market, it could have a material adverse effect on our business,
financial condition, results of operations or prospects.

The market sizes for our
product candidates have not been established with precision, and may be smaller than we estimate.

Our estimates of the markets for our
product candidates are based on a number of internal and third-party estimates, including, without limitation, the number of patients
with specified diseases and the assumed prices at which we will be able to sell any products we develop in various markets. While we believe
our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions
supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors.
As a result, our estimates of the total market for our current or future products may prove to be incorrect. If the actual number of patients
who would benefit from our products, the price at which we will be able to sell future products, or the annual total addressable market
for our products is smaller than we have estimated, it may impair future sales of any product we develop and have an adverse impact on
our business.

Interim, “top-line”
and preliminary data from our clinical studies that we announce or publish from time to time may change as more patient data become available
and are subject to audit and verification procedures that could result in